Free Trial
NASDAQ:ADAG

Adagene (ADAG) Stock Price, News & Analysis

Adagene logo
$1.88 -0.06 (-2.84%)
Closing price 07/3/2025 03:07 PM Eastern
Extended Trading
$1.80 -0.09 (-4.77%)
As of 05:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adagene Stock (NASDAQ:ADAG)

Key Stats

Today's Range
$1.79
$1.99
50-Day Range
$1.43
$2.09
52-Week Range
$1.33
$3.58
Volume
16,381 shs
Average Volume
63,515 shs
Market Capitalization
$88.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Adagene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

ADAG MarketRank™: 

Adagene scored higher than 40% of companies evaluated by MarketBeat, and ranked 652nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adagene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Adagene has received no research coverage in the past 90 days.

  • Read more about Adagene's stock forecast and price target.
  • Earnings Growth

    Earnings for Adagene are expected to decrease in the coming year, from ($0.60) to ($0.76) per share.

  • Price to Book Value per Share Ratio

    Adagene has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Adagene's valuation and earnings.
  • Percentage of Shares Shorted

    0.25% of the float of Adagene has been sold short.
  • Short Interest Ratio / Days to Cover

    Adagene has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adagene has recently increased by 28.12%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Adagene does not currently pay a dividend.

  • Dividend Growth

    Adagene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.25% of the float of Adagene has been sold short.
  • Short Interest Ratio / Days to Cover

    Adagene has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adagene has recently increased by 28.12%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Adagene has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Adagene this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Adagene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.51% of the stock of Adagene is held by institutions.

  • Read more about Adagene's insider trading history.
Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Adagene ADRs Rise Following Sanofi Investment
See More Headlines

ADAG Stock Analysis - Frequently Asked Questions

Adagene's stock was trading at $1.99 on January 1st, 2025. Since then, ADAG stock has decreased by 5.3% and is now trading at $1.8850.

Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Today
7/06/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADAG
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+324.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$100 thousand
Price / Cash Flow
N/A
Book Value
$1.14 per share
Price / Book
1.65

Miscellaneous

Free Float
37,123,000
Market Cap
$88.80 million
Optionable
Not Optionable
Beta
0.74
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ADAG) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners